We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Improving Pain Control in Paraesophageal Hernia Repair: Intravenous Lidocaine Versus Placebo (PEH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04096170
Recruitment Status : Recruiting
First Posted : September 19, 2019
Last Update Posted : June 13, 2022
Information provided by (Responsible Party):
Wake Forest University Health Sciences

Brief Summary:
We aim to study the impact of perioperative IV lidocaine on postoperative pain control in patients undergoing paraesophageal hernia repair. This is in the context of an established ERAS protocol. We wish to study the effect of IV Lidocaine on postoperative short and long-term outcomes, including patients' length of stay postoperative mortality, morbidity, and quality of life. We will compare this to our standard pain management.

Condition or disease Intervention/treatment Phase
Hernia, Paraesophageal Drug: IV lidocaine Drug: Placebo Phase 4

Detailed Description:
Patients will be prospectively enrolled from Carolinas Hernia Center's outpatient clinic. All paraesophageal hernia patients, age 18 and older, undergoing PEH repair at CHS will be included. We will conduct a two-arm prospective randomized study, IV Lidocaine versus placebo, to study the reduction of narcotics, return to bowel function and length of stay. Both arms will receive standard multimodal pain control in the operative and postoperative period. There will be two arms: 1. IV Lidocaine 2. Placebo. Subject participation will last approximately 6 months for this study. Lidocaine will be used as a perioperative adjunct. At the conclusion of the study, chart review will be performed to evaluate if Lidocaine infusion limited narcotic need, or effected Visual Analog Scale (VAS) values. VAS is the standard nursing method of documenting pain using pain scores. The nurses ask the patient to rate pain from 0 (no pain) to 10 (excruciating pain). LOS is a secondary endpoint of the study, as subjects in the lidocaine arm are hypothesized to have improved pain control and require lower narcotic dosing, potentially leading to earlier discharge. We will evaluate patient demographics, preoperative lab values, intraoperative and perioperative variables, as well as postoperative outcomes and pain reported by VAS. Postoperative data to be reviewed will also include total opioid analgesia administered, time from surgery to a clear liquid diet, time from surgery to a post-fundoplication diet, time to return of bowel function, length of stay, pain/VAS scores at 6 hours postoperatively, pain/VAS scores on each post-operative day until discharge, pain/VAS scores at 2 and 4 weeks, and pain/VAS scores at 6 months, infectious complications (urinary tract infections as well as surgical site infections, deep organ space infections, pneumonia), and non-infectious complications (stroke, myocardial infarction, respiratory failure, post-op bleeding, unplanned return to the OR, acute renal failure, death, etc.). When results of the study are published, the subject's identity will remain confidential. Data will be analyzed using standard statistical methods; all patient-identifying information will be removed prior to analysis. Descriptive statistics including means and standard deviations, medians and interquartile range, or counts and percentages, will be used to describe the study population on all variables. For continuous variables comparisons will be made between groups using t-tests and Wilcoxon Rank Sum test. For categorical variables, Chi-Square test and Kruskal-Wallis tests will be used for comparisons between groups. Multivariate regression will be performed as needed to control for potential confounding factors such as age, gender and type of procedure. A p-value of <0.05 will be used for all significance determinations. The SAS® system version 9.4 (Cary, NC) or similar program will be used to complete all statistical analyses.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Improving Pain Control in Paraesophageal Hernia Repair: Intravenous Lidocaine Versus Placebo
Actual Study Start Date : June 21, 2018
Estimated Primary Completion Date : January 1, 2024
Estimated Study Completion Date : July 1, 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: IV Lidocaine
100 mg Lidocaine bolus on induction, then an infusion of 1.5 mg/kg/hr to begin prior to incision, run throughout the operation and continues into PACU for 1 hour OR until one 2gm/250mL D5W bag has been infused, whichever occurs first. The Patient will be monitored by nursing staff with the aid of continuous cardiac monitoring in the PACU for at least 30 minutes after the discontinuation of the lidocaine drip.
Drug: IV lidocaine
Patients randomized to the IV lidocaine group will receive a 100 mg lidocaine bolus on induction then an infusion of 1.5 mg/kg/hr prior to incision. This infusion will continue throughout operation and into the PACU for 1 hour OR until the 2gm/250 mL D5W bag has been infused, whichever occurs first.

Placebo Comparator: Placebo
Patients will receive D5W solution at the same volume and rate as the IV lidocaine.
Drug: Placebo
o Patients randomized to the placebo group will receive D5W solution (as this is the carrier for lidocaine) at the same volume and rate as the IV lidocaine.

Primary Outcome Measures :
  1. Post-Op Morphine Equivalents [ Time Frame: Post-operation up to 6 months ]
    Post-operative consumption of morphine equivalents

  2. VAS Pain Score [ Time Frame: post-op to 6 months ]
    VAS is the standard nursing method of documenting pain using pain scores. The nurses ask the patient to rate pain from 0 (no pain) to 10 (excruciating pain).

  3. Length of Stay [ Time Frame: up to 6 months ]
    Length of stay post op

  4. Return of bowel function [ Time Frame: up to 6 months ]
    We will track when each patient passes first bowel movement expressed as hours since operation

  5. Day to toleration of diet [ Time Frame: up to 6 months ]
    When the patient tolerates a normal diet

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients aged 18+ years of age
  • American Association of Anesthesiologists (ASA) scores of I-III
  • Undergoing elective laparoscopic paraesophageal hernia repair including robotic assisted laparoscopic cases.
  • All paraesophageal hernia patients seen in clinic who meet inclusion criteria will be given the option to enroll.
  • Cases converted to open laparotomy or hand-assisted laparoscopy will be included for intention to treat analysis.
  • Patients who have complications of Clavien-Dindo class 3 or greater will be included in calculations of complication rates. However, they will not be included in calculations of postoperative morphine equivalents, as repeat intervention will confound the normal course of postoperative pain control.

Exclusion Criteria:

  • Patients with end stage renal disease
  • Patients with allergies to lidocaine and other amide local anesthetics.
  • Patients with contraindications to sodium channel blockers.
  • Patients with psychomotor retardation
  • Patients with body mass index >40 mg/kg2.
  • Patients receiving opioid pain medication in the previous week or taking daily medication for chronic pain
  • Patients with a seizure disorder
  • Patients with cardiac intraventricular conduction delays, congestive heart failure, first and second-degree heart conduction blocks.
  • Patients undergoing planned concomitant procedures other than PEH repair
  • Patients that are classified as ASA 4 or 5 during pre-operative anesthesia visit (if needed) will be excluded. Documentation from the pre-op visit will be reviewed by the research team prior to the surgery date.
  • Exclusion from all or portions will be at the discretion of the attending surgeon and anesthesiologist.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04096170

Layout table for location contacts
Contact: Greg Scarola 704-355-4135 gregory.scarola@atriumhealth.org

Layout table for location information
United States, North Carolina
Atrium Health - Carolinas Medical Center Recruiting
Charlotte, North Carolina, United States, 28203
Contact: Greg Scarola    704-355-4135    gregory.scarola@atriumhealth.org   
Principal Investigator: Paul D Colavita, MD         
Sponsors and Collaborators
Wake Forest University Health Sciences
Layout table for investigator information
Principal Investigator: Paul D Colavita, MD Wake Forest University Health Sciences
Layout table for additonal information
Responsible Party: Wake Forest University Health Sciences
ClinicalTrials.gov Identifier: NCT04096170    
Other Study ID Numbers: IRB00081332
06-18-03 ( Other Identifier: Atrium )
Pro00027862 ( Other Identifier: Atrium )
First Posted: September 19, 2019    Key Record Dates
Last Update Posted: June 13, 2022
Last Verified: March 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hernia, Hiatal
Pathological Conditions, Anatomical
Hernia, Diaphragmatic
Internal Hernia
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action